These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36749544)

  • 1. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
    Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
    Barratt J; Sulowicz W; Schömig M; Esposito C; Reusch M; Young J; Csiky B
    Adv Ther; 2021 Oct; 38(10):5345-5360. PubMed ID: 34523074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
    Provenzano R; Szczech L; Leong R; Saikali KG; Zhong M; Lee TT; Little DJ; Houser MT; Frison L; Houghton J; Neff TB
    Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
    Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
    Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
    Akizawa T; Ueno M; Shiga T; Reusch M
    Ther Apher Dial; 2020 Dec; 24(6):628-641. PubMed ID: 31891449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
    Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W
    Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
    Akizawa T; Otsuka T; Reusch M; Ueno M
    Ther Apher Dial; 2020 Apr; 24(2):115-125. PubMed ID: 31222951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials.
    Hamano T; Yamaguchi Y; Goto K; Martin S; Jiletcovici A; Dellanna F; Akizawa T; Barratt J
    Adv Ther; 2024 Apr; 41(4):1553-1575. PubMed ID: 38363466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD.
    Chertow GM; Pergola PE; Farag YMK; Agarwal R; Arnold S; Bako G; Block GA; Burke S; Castillo FP; Jardine AG; Khawaja Z; Koury MJ; Lewis EF; Lin T; Luo W; Maroni BJ; Matsushita K; McCullough PA; Parfrey PS; Roy-Chaudhury P; Sarnak MJ; Sharma A; Spinowitz B; Tseng C; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Eckardt KU;
    N Engl J Med; 2021 Apr; 384(17):1589-1600. PubMed ID: 33913637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3b, multicenter, open-label, single-arm study of roxadustat within a US dialysis organization: The DENALI study.
    Larkin J; Hymes J; Britton ML; Oluwatosin Y; Nolen J; Zhu L; Silva A
    Hemodial Int; 2024 Jan; 28(1):59-71. PubMed ID: 37875459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
    Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
    J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis.
    Eckardt KU; Agarwal R; Aswad A; Awad A; Block GA; Bacci MR; Farag YMK; Fishbane S; Hubert H; Jardine A; Khawaja Z; Koury MJ; Maroni BJ; Matsushita K; McCullough PA; Lewis EF; Luo W; Parfrey PS; Pergola P; Sarnak MJ; Spinowitz B; Tumlin J; Vargo DL; Walters KA; Winkelmayer WC; Wittes J; Zwiech R; Chertow GM
    N Engl J Med; 2021 Apr; 384(17):1601-1612. PubMed ID: 33913638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roxadustat Versus Epoetin Alfa for Treating Anemia in Patients with Chronic Kidney Disease on Dialysis: Results from the Randomized Phase 3 ROCKIES Study.
    Fishbane S; Pollock CA; El-Shahawy M; Escudero ET; Rastogi A; Van BP; Frison L; Houser M; Pola M; Little DJ; Guzman N; Pergola PE
    J Am Soc Nephrol; 2022 Apr; 33(4):850-866. PubMed ID: 35361724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
    Barratt J; Andric B; Tataradze A; Schömig M; Reusch M; Valluri U; Mariat C
    Nephrol Dial Transplant; 2021 Aug; 36(9):1616-1628. PubMed ID: 34077510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 3b, multicenter, open-label, single-arm study of roxadustat (ASPEN): Operational learnings within United States dialysis organizations.
    Fishbane S; Vishnepolsky M; Oluwatosin Y; Nolen J; Zhu L; Cooper K; Young A
    Hemodial Int; 2023 Oct; 27(4):400-410. PubMed ID: 37380364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients.
    Akizawa T; Tanaka-Amino K; Otsuka T; Yamaguchi Y
    Am J Nephrol; 2021; 52(9):702-713. PubMed ID: 34628408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
    Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
    N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and renal safety outcomes of hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat for anemia patients with chronic kidney disease: a systematic review and meta-analysis.
    Tian L; Wang M; Liu M; Pang Y; Zhao J; Zheng B; Wang Y; Zhao W
    Ren Fail; 2024 Dec; 46(1):2313864. PubMed ID: 38345037
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
    Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
    J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roxadustat for the treatment of anemia in patients with chronic kidney diseases: a meta-analysis.
    Zhang L; Hou J; Li J; Su SS; Xue S
    Aging (Albany NY); 2021 Jun; 13(13):17914-17929. PubMed ID: 34115611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.